Kaitlin Brau, MD
Endocrinology, Diabetes & Metabolism · Norfolk, NENPI 1780024380
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,560 of the $8,130 with a category attached, or 68.4%. 37 manufacturers reported payments, led by Insulet Corporation at 31.1% of the total. 2025 is the largest year on record at $3,153, 4.3 times the $738 reported in 2019.
Across 349 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- Lilly USA, LLC$1K
- Novo Nordisk$666
- Ascensia Diabetes Care US Inc.$530
- Amgen$316
- Sanofi-aventis U.S. LLC$286
- plus $3K from 31 others
What the payments were for
- Travel & lodging$2,12126%
- Food & beverage$5,56068%
- Education$4506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 23 | $2,531 |
| Lilly USA, LLC | 74 | $1,002 |
| Novo Nordisk | 41 | $666 |
| Ascensia Diabetes Care US Inc. | 10 | $530 |
| Amgen | 21 | $316 |
| Sanofi-aventis U.S. LLC | 16 | $286 |
| Bayer | 16 | $266 |
| Corcept Therapeutics | 15 | $250 |
| Xeris Pharmaceuticals, Inc. | 12 | $225 |
| Recordati_rare_diseases_inc. | 10 | $201 |
| AstraZeneca(2 entities) | 15 | $199 |
| Tandem Diabetes Care, Inc. | 11 | $166 |
| Boehringer Ingelheim | 10 | $156 |
| Medtronic(2 entities) | 7 | $142 |
| Abbott | 6 | $140 |
| Merck | 8 | $110 |
| Amarin Pharma, Inc. | 6 | $102 |
| Zealand Pharma US, Inc. | 7 | $101 |
| Mannkind Corporation | 5 | $85 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Kyowa Kirin, Inc. | 4 | $64 |
| Dexcom, Inc. | 4 | $62 |
| Chiesi USA, Inc. | 3 | $62 |
| Kvk-tech, Inc. | 1 | $59 |
| Astellas Pharma US Inc | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| Shire North American Group Inc | 3 | $44 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| IBSA Pharma Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Valeritas, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,130 in reported general payments places this provider in the 75th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 250 | $315,395 |
| MounjaroTirzepatide | 122 | $130,790 |
| TrulicityDulaglutide | 97 | $101,010 |
| JardianceEmpagliflozin | 96 | $89,264 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $71,688 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $67,050 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $65,411 |
| FarxigaDapagliflozin Propanediol | 89 | $64,557 |
| KerendiaFinerenone | 72 | $56,738 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $56,385 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $51,201 |
| Novolog FlexpenInsulin Aspart | 88 | $29,225 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $20,612 |
| RybelsusSemaglutide | 18 | $18,656 |
| Humalog Kwikpen U-100Insulin Lispro | 69 | $18,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $666 | $352,497320 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,002 | $244,506286 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $156 | $106,719125 claims |
| AstraZenecaFarxiga | $199 | $64,55789 claims |
| BayerKerendia | $266 | $56,73872 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Norfolk
- Enas Al ZaghalNorfolk$5K
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Shannon WakeleyLincoln$78K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.